Soleno Therapeutics (SLNO) Income towards Parent Company (2016 - 2017)
Historic Income towards Parent Company for Soleno Therapeutics (SLNO) over the last 5 years, with Q4 2017 value amounting to -$544000.0.
- Soleno Therapeutics' Income towards Parent Company rose 5434.69% to -$544000.0 in Q4 2017 from the same period last year, while for Sep 2018 it was -$544000.0, marking a year-over-year increase of 8717.16%. This contributed to the annual value of -$175.8 million for FY2024, which is 35315.16% down from last year.
- Latest data reveals that Soleno Therapeutics reported Income towards Parent Company of -$544000.0 as of Q4 2017, which was up 5434.69% from -$1.3 million recorded in Q3 2017.
- In the past 5 years, Soleno Therapeutics' Income towards Parent Company ranged from a high of -$544000.0 in Q4 2017 and a low of -$4.3 million during Q1 2016
- Over the past 5 years, Soleno Therapeutics' median Income towards Parent Company value was -$1.4 million (recorded in 2013), while the average stood at -$1.9 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 37925.27% in 2014, then surged by 8024.87% in 2017.
- Quarter analysis of 5 years shows Soleno Therapeutics' Income towards Parent Company stood at -$869278.0 in 2013, then plummeted by 379.25% to -$4.2 million in 2014, then rose by 15.85% to -$3.5 million in 2015, then skyrocketed by 66.01% to -$1.2 million in 2016, then soared by 54.35% to -$544000.0 in 2017.
- Its Income towards Parent Company stands at -$544000.0 for Q4 2017, versus -$1.3 million for Q3 2017 and -$913000.0 for Q2 2017.